Tvardi Therapeutics, Inc.

Tvardi Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapies for fibrosis-driven diseases and certain cancers. Its pipeline centers on TTI-101 and TTI-109, with development programs spanning preclinical and early clinical stages.

2.86

2.77

— Tvardi Therapeutics, Inc.
%
Clinical-stage product candidates0% Small-molecule drug candidates in clinical and early development.
Preclinical pipeline0% Discovery-stage programs for additional fibrosis and oncology indications.
Research and development activities100% Internal and outsourced work to advance target biology, chemistry, and trials.

Tvardi does not currently sell approved products, so it has no commercial customer base today...

  • Physicians and treatment centersprimary

    Would prescribe Tvardi's therapies if approved for fibrosis or oncology indications.

  • Third-party payorsprimary

    Medicare, Medicaid, and managed care organizations that influence access and uptake.

  • Patients with fibrosis-driven diseasesprimary

    Potential end users for TTI-101 and TTI-109 in diseases such as IPF.

  • Oncology patientssecondary

    Potential end users for TTI-101 in HCC and other solid tumors.

  • Strategic partnerssecondary

    Pharma or biotech collaborators that may license or co-develop programs.

Tvardi is headquartered in the United States and operates as a U.S.-based biopharmaceutical developer...

  • •Headquartered and operated in the United States
  • •Clinical and regulatory pathway is primarily U.S.-based
  • •Competes with global biopharma companies worldwide
  • •No disclosed country revenue mix because no product revenue exists
  • •Future commercialization could expand beyond the U.S.

Tvardi’s strategy is to advance TTI-101 and TTI-109 through clinical and preclinical development toward regulatory...

01
Advance lead programs through development milestonesshort-term

Clinical progress is the main value driver for a company without approved products.

02
Secure additional fundingshort-term

Development-stage biopharma requires ongoing capital before any product revenue.

03
Build a broader pipeline in fibrosis and oncologymedium-term

Multiple shots on goal can improve the chance of creating a viable commercial asset.

Tvardi faces the typical risks of a clinical-stage biopharmaceutical company: uncertain trial outcomes, regulatory...

critical

Clinical development failure

TTI-101 and TTI-109 are still in early development and may not show adequate efficacy or safety.

Scope
Lead programs
Materiality
high
critical

Financing and going-concern risk

The company expects to need substantial additional funding and may not obtain it on acceptable terms.

Scope
Corporate liquidity
Materiality
high
high

Commercial adoption and reimbursement risk

Even approved therapies may face limited physician uptake or payor coverage.

Scope
Future product sales
Materiality
high
high

Competition from larger drug developers

Major biopharma companies have greater resources and may reach the market first.

Scope
Fibrosis and HCC indications
Materiality
high
medium

Limited operating history

The company has a short track record, making execution and forecasting difficult.

Scope
Corporate execution
Materiality
medium
Prepaid and accrued research and development costs
R&D expense and liabilities
Stock-based compensation
Operating expenses and equity
Fair value of short-term investments
Cash equivalents, investments, and earnings
Acquisition accounting and impairment
Assets, goodwill/intangibles, and future charges

Trevi Therapeutics, Inc.

TRVI · Pharmaceutical Preparations

Calidi Biotherapeutics, Inc.

CLDI · Biological Products, (No Diagnostic Substances)

TG THERAPEUTICS, INC.

TGTX · Pharmaceutical Preparations

TScan Therapeutics, Inc.

TCRX · Biological Products, (No Diagnostic Substances)

Aardvark Therapeutics, Inc.

AARD · Pharmaceutical Preparations

Atara Biotherapeutics, Inc.

ATRA · Biological Products, (No Diagnostic Substances)

: 29/04/2026